Status:
UNKNOWN
Imidapril and Candesartan on Fibrinolysis and Insulin-Sensitivity in Patients With Mild to Moderate Hypertension
Lead Sponsor:
University of Pavia
Conditions:
Essential Hypertension
Eligibility:
All Genders
18-65 years
Phase:
PHASE3
Brief Summary
BACKGROUND The effects of ACE-inhibitors on fibrinolysis are well documented. Experimental and clinical studies have shown that ACE inhibitors induce a reduction in plasma PAI-1 levels in many cardiov...
Eligibility Criteria
Inclusion
- Age 18-65 years
- DBP ≥ 90 \< 110 mmHg and SBP ≥ 140 \< 180 mmHg
- Normal Body Mass Index (BMI) (≤ 25 Kg/m2)
- Normal kidney function (Creatinine Clearance \> 80 ml/min)
- Normocholesterolemia (TC \< 250 mg/dl)
- At least one of the following risk factor:
- age (M \> 55 years)
- smoking
- family history of premature CV disease
- echocardiographic LVH
- carotid wall thickening (IMT \> 0.9 mm)
- ankle/brachial BP \< 0.9
Exclusion
- Secondary hypertension
- Overweight or obese state (BMI ≥ 25 Kg/m2)
- Suspected history of allergy to the ARBs, or ACEs
- Malignancy
- Renal, hepatic, endocrine, or gastrointestinal disease
- Women who are pregnant and lactating
- Women child-bearing potential
- Heart failure
- AMI and/or stroke in the previous 6 months
- CHD
- Diabetes mellitus
Key Trial Info
Start Date :
March 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2009
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT00644475
Start Date
March 1 2008
End Date
March 1 2009
Last Update
March 26 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Pavia
Pavia, Italy, 27100